Premium
A step‐wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD
Author(s) -
LI Huiping,
HE Guojun,
CHU Haiqing,
ZHAO Lan,
YU Hui
Publication year - 2003
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1046/j.1440-1843.2003.00468.x
Subject(s) - medicine , methylprednisolone , exacerbation , prednisone , copd , dexamethasone , corticosteroid , anesthesia , asthma , group b , glucocorticoid , gastroenterology
Objective: The aim of the study was to explore the clinical value of a step‐wise application of methylprednisolone (MP) compared to dexamethasone (DXM) in acute exacerbations of COPD. Methodology: One hundred and forty‐two patients with an acute exacerbation of COPD were divided randomly into two groups: 71 patients were treated with MP and the other 71 patients were treated with DXM. Otherwise each group was given the same basic treatments: antibiotics, bronchodilators, oxygen therapy as well as standard hospital care. The patients in the MP group were given a tapering dose of MP for 7–14 days, and the patients in the DXM group were given a corresponding tapering dose of DXM for 7–14 days. Then both groups were given a gradually reducing dose of oral prednisone for 2–3 weeks. Two weeks before the prednisone was tapered off, inhaled corticosteroid was introduced. The patients’ symptom scores, physical signs, per cent predicted FEV 1 %, and arterial blood gases were monitored before treatment and after the seventh day of treatment. Results: There was an obvious improvement in symptoms after 1–3 days in all 71 patients in the MP group, with their wheezing being distinctly reduced or disappearing entirely. The maximum benefit that occurred in the MP group (90.14%) was considerably higher than that of the DXM group (25.35%), P < 0.05. The predicted FEV 1 % in the MP group increased from 46.7 ± 10.6 to 67.5 ± 12.4, compared with an increase in the DXM group from 50.1 ± 7.6 to 58.9 ± 10.8. The difference between the two groups was significant ( P < 0.05). Conclusions: An adequate and tapering dose of MP used in acute exacerbations of COPD can relieve the inflammatory reaction in airways and reduce airway spasm more promptly than DXM.